Elekta eyes Turkish radiology market with acquisition of Mesi Medikal
AMIC looks to down-classify brachytherapy’s FDA status
Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.
Breast cancer: Judge stays C.R. Bard suit against Hologic over Mammosite device
iCad soars on Medicare reimbursement nod | Wall Street Beat
Cancer research: Varian awards $100k for radiation therapy registry
Varian Medical Systems (NYSE:VAR), a medical device and software manufacturer focused on radiation-based cancer treatment, awarded a $100,000 grant to the American Board of Radiology Foundation to support a national brachytherapy registry.
Elekta Completes the Acquisition of Nucletron
Elekta AB (publ) (STO:EKTAB) today announced it has successfully
completed its acquisition of Nucletron, the world leader in
brachytherapy treatment planning and delivery. Through the combination
Elekta will offer a complete range of radiotherapy planning and delivery
technologies. As the market leader in Europe and with strong positions
in North America and Asia, Elekta will enhance the combined ability to
meet the clinical needs of cancer patients and health care providers
throughout the world.
“Now we have successfully completed the acquisition and we are very
enthusiastic about building a broader, stronger and highly complementary
range of cutting-edge cancer care solutions”
iCad sued for device acquired in Xoft Inc. acquisition
Xoft Inc. could turn out to be a lot more expensive for iCad (NSDQ:ICAD) than the $1 million in cash and the 8.47 million shares of stock it paid for the oncology device manufacturer late last year.
Theragenics swings to Q4, 2009 black
Theragenics Corp. (NYSE:TGX) posted fourth-quarter sales of $18.7 million for the three months ended Dec. 31, 2009, up 3.2 percent compared with $18.1 million during the same period in 2008. Net income was $389,000, compared with net losses of $62.5 million during Q4 2008:
Press Release
Theragenics® Reports Record Revenue with
2009 Results
$78.3 Million is Highest Annual Revenue in 29-Year History
